TrialSignal
Clinical trial intelligence report
Quantification of Bacterial DNA in Septic Intensive Care Patients in Relation to Concentration of Antibiotics and Clinical Outcome: A Prospective Observation Study
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT03782454
Status
UNKNOWN
Phase
Observational Study
Sponsor
Region Örebro County
Executive brief
Investment-Ready Snapshot
This study, sponsored by Region Örebro County, aims to establish ddPCR as a diagnostic tool for assessing bacterial load and treatment efficacy in septic patients. Given the high mortality rates associated with sepsis and the challenges in timely diagnosis and treatment, successful validation of this method could address significant unmet medical needs in critical care. The findings may enhance antibiotic stewardship and reduce the incidence of antibiotic resistance, positioning ddPCR as a valuable asset in the sepsis management market. The potential for commercialization hinges on demonstrating clinical utility and integration into existing diagnostic workflows, which could attract interest from diagnostic companies and pharmaceutical partners.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03782454
Indication
Septic Shock
Modality
RNA therapy
Target
Bacterial DNA clearance measured with droplet digital Polymerase Chain Reaction (ddPCR) as a biomarker for bacterial load in septic patients.
Intervention
Blood sampling
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.